The 2019 ESC-EASD guidelines on diabetes recommend DPP4i administration only when HbA1c targets are not reached after therapy with SGLT-2 inhibitors, metformin and/or GLP-1 receptor agonists [10]. This evidence concerns the gene GLP1R and diabetes mellitus.